Devimistat

Devimistat
Clinical data
Other names	CPI-613
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 6,8-Bis(benzylsulfanyl)octanoic acid;
CAS Number	95809-78-2;
PubChem CID	24770514;
DrugBank	12109;
ChemSpider	28189062;
UNII	E76113IR49;
ChEMBL	ChEMBL3186849;
CompTox Dashboard (EPA)	DTXSID70914807 ;
ECHA InfoCard	100.231.125
Chemical and physical data
Formula	C22H28O2S2
Molar mass	388.58 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC=C(C=C1)CSCCC(CCCCC(=O)O)SCC2=CC=CC=C2;
	InChI InChI=1S/C22H28O2S2/c23-22(24)14-8-7-13-21(26-18-20-11-5-2-6-12-20)15-16-25-17-19-9-3-1-4-10-19/h1-6,9-12,21H,7-8,13-18H2,(H,23,24); Key:ZYRLHJIMTROTBO-UHFFFAOYSA-N;

Devimistat (INN; development code CPI-613) is an experimental anti-mitochondrial drug being developed by Cornerstone Pharmaceuticals.^[1] It is being studied for the treatment of patients with metastatic pancreatic cancer and relapsed or refractory acute myeloid leukemia (AML).

Devimistat's mechanism of action differs from other drugs, operating on the tricarboxylic acid cycle and inhibiting enzymes involved with cancer cell energy metabolism. A lipoic acid derivative different from standard cytotoxic chemotherapy, devimistat is currently being studied in combination with modified FOLFIRINOX to treat various solid tumors and heme malignancies.

Regulation[edit]

The U.S. Food and Drug Administration (FDA) has designated devimistat as an orphan drug for the treatment of pancreatic cancer, AML, myelodysplastic syndromes (MDS), peripheral T-cell lymphoma, and Burkitt's lymphoma, and given approval to initiate clinical trials in pancreatic cancer and AML.^{[citation needed]}

Clinical trials[edit]

Clinical trials of the drug are underway including a Phase III open-label clinical trial^[2] to evaluate efficacy and safety of devimistat plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas.^{[citation needed]}

References[edit]

^ "CPI-613". Cornerstone Pharmaceuticals.
^ Philip PA, Buyse ME, Alistar AT, Rocha Lima CM, Luther S, Pardee TS, Van Cutsem E (October 2019). "A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas". Future Oncology. 15 (28): 3189–3196. doi:10.2217/fon-2019-0209. PMC 6854438. PMID 31512497.

[1] "CPI-613". Cornerstone Pharmaceuticals.

[2] Philip PA, Buyse ME, Alistar AT, Rocha Lima CM, Luther S, Pardee TS, Van Cutsem E (October 2019). "A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas". Future Oncology. 15 (28): 3189–3196. doi:10.2217/fon-2019-0209. PMC 6854438. PMID 31512497.

[1]

[2]